Unravel Biosciences, Inc. filed a Form D with the Securities and Exchange Commission on 2021-08-06.
Unravel Biosciences, Inc. filed a Form D notice of an exempt securities offering with the SEC on August 6, 2021. The filing reports $500K sold. It names Richard Novak (Executive Officer, Director), Frederic Vigneault (Executive Officer, Director), Donald Ingber (Director) (SEC Form D, August 6, 2021).
Sell to companies like Unravel Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2021-08-06 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Unravel Biosciences, Inc.
Free to see. No signup.
More on the people and the money behind Unravel Biosciences, Inc., from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when Unravel Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Unravel Biosciences, Inc. raises, hires or launches. No email unless you switch it on.
Watch Unravel Biosciences, Inc. →Get the full cited report on Unravel Biosciences, Inc.
What the filing shows about Unravel Biosciences, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Unravel Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Unravel Biosciences, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Unravel Biosciences, Inc. See pricing
Each marker is one filing. The larger marker is the filing this page is about.
By form type: D ×3.
What the filing shows about Unravel Biosciences, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Unravel Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Unravel Biosciences, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The 3 most recent of 3 filings on CIK 0001876967, filed as Unravel Biosciences, Inc.. Read from the SEC's own submissions feed for this issuer, not from a third party. Incorporated in DE. Full history on sec.gov.
Checked away from the filing. What is below does not come from the record on sec.gov.
The title and description the site itself served, answering 200, after redirecting from https://unravel.bio. Not a cached copy and not the company's directory entry — what was live when we asked.
Richard Novak is named as Executive Officer and Director on the Form D that Unravel Biosciences, Inc. filed with the SEC on 6 August 2021, one of 4 people that filing names.
Frederic Vigneault is named as Executive Officer and Director on the Form D that Unravel Biosciences, Inc. filed with the SEC on 6 August 2021, one of 4 people that filing names.
Donald Ingber is named as Director on the Form D that Unravel Biosciences, Inc. filed with the SEC on 6 August 2021, one of 4 people that filing names.
Lewis Geffen is named as Executive Officer on the Form D that Unravel Biosciences, Inc. filed with the SEC on 6 August 2021, one of 4 people that filing names.
4 people named on the filing — 3 holding an executive role and 1 as a director only.
Named as of the 2021-08-06 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Unravel Biosciences, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Unravel Biosciences, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-28 (unravel.bio).
Each opens in a new tab, filled in for Unravel Biosciences, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Boston
https://mentionfox.com/funding/unravel-biosciences-inc-form-d-000001